Overview
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
Status:
Unknown status
Unknown status
Trial end date:
2017-12-01
2017-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is an open-label brain PET/CT (positron emission tomography/computed tomography) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in glioma patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 (≤40 µg BNOTA-PRGD2) will be intravenously injected into patients in suspicion of glioma. Visual and semiquantitative method will be used to assess the PET/CT images. Brain MRI with/without enhancement and 18F-FDG PET/CT will be performed for comparison. The postoperative pathology and integrin αvβ3 and CD34 immunohistochemical stains will also be used for correlation.Phase:
Early Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Peking Union Medical College HospitalCollaborator:
Beijing Tiantan HospitalCriteria
Inclusion Criteria:- Males and females, ≥18 years old;
- In suspicion of brain glioma on MRI;
- The tumor will be surgically removed and histological diagnosis will be available.
Exclusion Criteria:
- Females planning to bear a child recently or with childbearing potential;
- Known severe allergy or hypersensitivity to IV radiographic contrast;
- Inability to lie still for the entire imaging time because of cough, pain, etc.
- Inability to complete the needed examinations due to severe claustrophobia, radiation
phobia, etc.
- Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in
the opinion of the investigator, may significantly interfere with study compliance.